CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 104 enrolled
Drug / intervention
Octreotide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02474914
NCT02474914N/ACompleted

Efficacy of Octreotide in the Prevention of Postoperative Complications After Pancreaticodudenectomy in Patients With Soft Pancreas and Non-dilated Pancreatic Duct: A Prospective Randomized Trial"

Mansoura University·interventional·Posted Jun 18, 2015·Updated Aug 22, 2017

In Brief

A clinical study evaluating Octreotide and Placebo for Periampullary Carcinoma Resectable. Completed, enrolled 104 participants across 1 site.

Detailed Summary

pancreaticoduodenectomy (PD) is the standard operation for treatment of patients with benign and malignant pancreatic and periampullary diseases. Despite improved surgical technique and postoperative care, the mortality rate after PD is high reaching up to 30%, due to high incidence of postoperative complications . Pancreatic fistula (PF) is the one of the most frequent complications of PD and the major contributor to postoperative morbidity The aim of this study to evaluate the effect of the perioperative octreotide use after PD for prevention of the postoperative pancreatic fistula. The secondary outcomes are overall postoperative complications, mortality and the cost benefit relationship of the use of the perioperative octreotide.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesEgypt
Collaborators--

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJun 18, 2015
Enrollment StartMay 1, 2014
Primary CompletionApr 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 11.0 years ago

Interventions

Octreotidedrug

Octreotide will be given after PD

Placebodrug

Octreotide will NOT be given after PD